HSBC raises Sino Biopharmaceutical's target price to 58 Hong Kong dollars, with first-half revenue beating expectations

GoldenOctober2024

2024-09-16 05:12:50

Abstract generation in progress

The September 16th data from Golden Ten shows that HSBC Global Research has released a report stating that Innovent Biologics (01801.HK) has exceeded the bank’s and market expectations in the first half of the year, with promising prospects for PD-1 and IL-2, which can support business development opportunities. The buy rating is maintained, and the target price has been raised from 55 Hong Kong dollars to 58 Hong Kong dollars. The bank has raised its revenue forecast for 2024 to 2026 by 2 to 6%. HSBC Research expects Innovent Biologics’ revenue from 2024 to 2026 to rise by 28 to 32%, reaching breakeven in 2025. Calculated at 8 times the 2024 price-to-sales ratio, breakeven is approaching, and with the launch of multiple innovative drugs from 2024 to 2025 as a catalyst, the valuation of Innovent Biologics is considered attractive.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes